286 related articles for article (PubMed ID: 24460307)
1. Clinicopathologic characteristics of male breast cancer: a report of 21 cases in radiotherapy center of hamedan, iran.
Sedighi A; Hamed EA; Mohammadian K; Behnood S; Kalaghchi B
Asian Pac J Cancer Prev; 2013; 14(12):7381-3. PubMed ID: 24460307
[TBL] [Abstract][Full Text] [Related]
2. Breast Cancer in Men: a Report from the Department of Radiation Oncology in Kermanshah Province, Iran.
Amirifard N; Sadeghi E
Asian Pac J Cancer Prev; 2016; 17(5):2593-6. PubMed ID: 27268636
[TBL] [Abstract][Full Text] [Related]
3. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
[TBL] [Abstract][Full Text] [Related]
4. Male breast cancer: A 10 year retrospective case series in a tertiary care hospital.
Yetkin G; Celayir MF; Tanik C; Citgez B; Uludag M; Mihmanli M
J Pak Med Assoc; 2019 Aug; 69(8):1209-1212. PubMed ID: 31431782
[TBL] [Abstract][Full Text] [Related]
5. Human epidermal growth factor receptor-2 positivity predicts locoregional recurrence in patients with T1-T2 breast cancer.
Cefaro GA; Genovesi D; Trignani M; DI Nicola M
Anticancer Res; 2014 Mar; 34(3):1207-12. PubMed ID: 24596361
[TBL] [Abstract][Full Text] [Related]
6. Outcome of non-metastatic male breast cancer: 118 patients.
Arslan UY; Oksüzoğlu B; Ozdemir N; Aksoy S; Alkış N; Gök A; Kaplan MA; Gümüş M; Berk V; Uncu D; Baykara M; Colak D; Uyetürk U; Türker I; Işıkdoğan A
Med Oncol; 2012 Jun; 29(2):554-60. PubMed ID: 21573973
[TBL] [Abstract][Full Text] [Related]
7. Expressional correlation of human epidermal growth factor receptor 2, estrogen/progesterone receptor and protein 53 in breast cancer.
Panahi M; Saki N; Ashourzadeh S; Rahim F
Asian Pac J Cancer Prev; 2013; 14(6):3699-703. PubMed ID: 23886168
[TBL] [Abstract][Full Text] [Related]
8. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
[TBL] [Abstract][Full Text] [Related]
9. Om.breast cancer in very young women aged 25 year-old or below in the center of Tunisia and review of the literature.
Ben Abdelkrim S; Fathallah K; Rouatbi R; Ayachi M; Hmissa S; Mokni M
Pathol Oncol Res; 2015 Jul; 21(3):553-61. PubMed ID: 25962349
[TBL] [Abstract][Full Text] [Related]
10. The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival.
Tarhan MO; Demir L; Somali I; Yigit S; Erten C; Alacacioglu A; Ellidokuz H; Seseogullari O; Kucukzeybek Y; Can A; Dirican A; Bayoglu V; Akyol M
Clin Exp Metastasis; 2013 Feb; 30(2):201-13. PubMed ID: 22915160
[TBL] [Abstract][Full Text] [Related]
11. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic characteristics at diagnosis and the survival of patients with medullary breast carcinoma in China: a comparison with infiltrating ductal carcinoma-not otherwise specified.
Cao AY; He M; Huang L; Shao ZM; Di GH
World J Surg Oncol; 2013 Apr; 11():91. PubMed ID: 23607710
[TBL] [Abstract][Full Text] [Related]
14. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
15. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
[TBL] [Abstract][Full Text] [Related]
16. [Breast ductal carcinoma in situ with microinvasion: pathological review and clinical implications].
Modesto A; Gandy C; Mery E; Filleron T; Massabeau C; Izar F; Charitansky H; Roché H; de Lafontan B
Cancer Radiother; 2014 Mar; 18(2):107-10. PubMed ID: 24637020
[TBL] [Abstract][Full Text] [Related]
17. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component.
Yu KD; Wu LM; Liu GY; Wu J; Di GH; Shen ZZ; Shao ZM
Ann Surg Oncol; 2011 May; 18(5):1342-8. PubMed ID: 21042943
[TBL] [Abstract][Full Text] [Related]
18. Implications of New Lumpectomy Margin Guidelines for Breast-Conserving Surgery: Changes in Reexcision Rates and Predicted Rates of Residual Tumor.
Merrill AL; Coopey SB; Tang R; McEvoy MP; Specht MC; Hughes KS; Gadd MA; Smith BL
Ann Surg Oncol; 2016 Mar; 23(3):729-34. PubMed ID: 26467458
[TBL] [Abstract][Full Text] [Related]
19. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
Margalit DN; Sreedhara M; Chen YH; Catalano PJ; Nguyen PL; Golshan M; Overmoyer BA; Harris JR; Brock JE
Ann Surg Oncol; 2013 Mar; 20(3):811-8. PubMed ID: 22956068
[TBL] [Abstract][Full Text] [Related]
20. [Clinicopathologic analysis of the nipple-areolar complex occult involvement in early stage breast carcinoma].
Wang SY; Peng DF; Cai ZG; Zhang RZ; Yao TJ; Zhang H; Yang M; Dong HM
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):203-6. PubMed ID: 18756937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
